Development and validation of a new LC-MS/MS method for determining the concentration of the free fraction of tacrolimus in plasma depending on the expression of CYP3A5
Project Title
Rozwinięcie i walidacja nowej metody LC-MS/MS oznaczania stężenia wolnej frakcji tacrolimusu w osoczu w zależności od ekspresji CYP3A5
Financing Institution
Lead
lek. med. Karola Warzyszyńska
Subject
Rozwinięcie i walidacja nowej metody LC-MS/MS oznaczania stężenia wolnej frakcji tacrolimusu w osoczu w zależności od ekspresji CYP3A5
Project Objective
The aim of this project is to evaluate clinical usefulness of different TDM protocols in patients after kidney and liver transplantation, which include measurements of C0 and AUC in the whole blood and free TAC C0 in plasma ultrafiltrate. Additionally, the significance of CYP3A5 variant on TAC concentrations will be addressed. The values will be correlated with clinical endpoints such as BPAR and adverse drug effects.